Advances in pathogenesis, diagnosis and treatment of adrenocorticotropic pituitary adenomas

doi:10.3877/cma.j.issn.2095-123X.2020.02.012

Abstract

Abstract:

Adrenocorticotropic pituitary adenomas, also known as Cushing’s disease (CD), is caused by the autonomic secretion of adrenocorticotropic hormone by pituitary tumor, which leads to the excessive secretion of cortisol by adrenal gland. To clarify the pathogenesis of CD is helpful for diagnosis and treatment of the disease, and it is also of great significance for improving the clinical performance and prognosis evaluation of patients. This article reviews the literature on the pathogenesis and diagnosis and treatment of CD.

Key words: Cushing’s disease, Pituitary, Adrenocorticotropic hormone, Pathogenesis

Zhitao Wang, Chuan Zhang. Advances in pathogenesis, diagnosis and treatment of adrenocorticotropic pituitary adenomas[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2020, 10(02): 120-122.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2020.02.012

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2020/V10/I02/120

References 30

[1]	Bray GA. Harvey cushing and the neuroendocrinology of obesity[J]. Obes Res, 1994, 2(5): 482-485.
[2]	Ragnarsson O, Olsson DS, Chantzichristos D, et al. The incidence of Cushing’s disease: a nationwide Swedish study[J]. Pituitary, 2019, 22(2): 179-186.
[3]	Goodman RL. Diagnosis and differential diagnosis of Cushing’s syndrome[J]. N Engl J Med, 2017, 377(2): e3.
[4]	Pertichetti M, Serioli S, Belotti F, et al. Pituitary adenomas and neuropsychological status: a systematic literature review[J]. Neurosurg Rev, 2020, 43(4): 1065-1078.
[5]	Sahu JK, Vaddi VK, Negi S. Review of west syndrome: concerns on optimum dose of adrenocorticotrophic hormone[J]. Clin Drug Investig, 2018, 38(6): 563-564.
[6]	Ballmann C, Thiel A, Korah HE, et al. USP8 mutations in pituitary cushing adenomas-targeted analysis by next-generation sequencing[J]. J Endocr Soc, 2018, 2(3): 266-278.
[7]	Faucz FR, Tirosh A, Tatsi C, et al. Somatic USP8 gene mutations are a common cause of pediatric Cushing disease[J]. J Clin Endocrinol Metab, 2017, 102(8): 2836-2843.
[8]	Sbiera S, Kunz M, Weigand I, et al. The new genetic landscape of Cushing’s disease: deubiquitinases in the spotlight[J]. Cancers (Basel), 2019, 11(11): 1176.
[9]	Pérez-Rivas LG, Theodoropoulou M, Puar TH, et al. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor[J]. Eur J Endocrinol, 2018, 178(1): 57-63.
[10]	Perez-Rivas LG, Oβwald A, Knosel T, et al. Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome[J]. Endocr Relat Cancer, 2017, 24(9): L73-L77.
[11]	Sesta A, Cassarino MF, Terreni M, et al. Ubiquitin-specific protease 8 mutant corticotrope adenomas present unique secretory and molecular features and shed light on the role of ubiquitylation on ACTH processing[J]. Neuroendocrinology, 2020, 110(1-2): 119-129.
[12]	Albani A, Theodoropoulou M, Reincke M. Genetics of Cushing’s disease[J]. Clin Endocrinol (Oxf), 2018, 88(1): 3-12.
[13]	Lin SJ, Yang DR, Yang G, et al. TR2 and TR4 orphan nuclear receptors: an overview[J]. Curr Top Dev Biol, 2017, 125: 357-373.
[14]	Albani A, Perez-Rivas LG, Reincke M, et al. Pathogenesis of Cushing disease: an update on the genetics of corticotropinomas[J]. Endocr Pract, 2018, 24(10): 907-914.
[15]	Bergna C, Marin GH, Maiz M, et al. New forms of induction of apoptosis in aggressive lymphoma using peptides that interrupt the RAS/RAF interaction[J]. Ceylon Med J, 2019, 64(2): 46-51.
[16]	Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M. Medical management of Cushing’s syndrome: current and emerging treatments[J]. Drugs, 2019, 79(9): 935-956.
[17]	Sakakibara K, Tsujioka T, Kida JI, et al. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway[J]. Int J Hematol, 2019, 110(2): 213-227.
[18]	Zhang D, Bergsneider M, Wang MB, et al. Targeting the ERK pathway for the treatment of Cushing’s disease[J]. Oncotarget, 2016, 7(43): 69149-69158.
[19]	Casals G, Hanzu FA. Cortisol measurements in Cushing’s syndrome: immunoassay or mass spectrometry?[J]. Ann Lab Med, 2020, 40(4): 285-296.
[20]	Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome[J]. N Engl J Med, 1991, 325(13): 897-905.
[21]	Wang H, Hou B, Lu L, et al. PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study[J]. J Nucl Med, 2018, 59(3): 523-528.
[22]	Melmed S. Pituitary-tumor endocrinopathies[J]. N Engl J Med, 2020, 382(10): 937-950.
[23]	Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2017, 102(3): 709-757.
[24]	Post KD, Pain M, Zarzour H, et al. Transsphenoidal surgery for Cushing’s disease//Laws E Jr, Cohen-Gadol A, Schwartz T, et al. Transsphenoidal Surgery[M]. Berlin: Springer, Cham, 2017: 427-439.
[25]	Mehta GU, Ding D, Patibandla MR, et al. Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study[J]. J Clin Endocrinol Metab, 2017, 102(11): 4284-4291.
[26]	Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing’s syndrome[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 300-312.
[27]	Nishioka H, Yamada S. Cushing’s disease[J]. J Clin Med, 2019, 8(11): 1951.
[28]	Belokovskaya R, Ravikumar A, Arumugam D, et al. Mifepristone treatment for mild autonomous cortisol secretion due to adrenal adenomas: a pilot study[J]. Endocr Pract, 2019, 25(8): 846-853.
[29]	Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 17-26.
[30]	Tritos NA, Biller BMK. Current management of Cushing’s disease[J]. J Intern Med, 2019, 286(5): 526-541.

Please choose a citation manager

Content to export